$13.25
-0.09-0.67%
At close: -
$13.25
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Arrowhead Pharma Insider Trading Activity | NASDAQ:ARWR | Benzinga
Track the latest Arrowhead Pharma insider trading activity. Stay informed on recent buys, sells, and market impact for Arrowhead Pharma stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Arrowhead Pharmaceuticals Inc Insiders Doing?
At Arrowhead Pharmaceuticals Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 141.12K shares worth $1.53M, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
- On January 27, 2025, Adeoye Olukotun, the company's DIRECTOR sold 959 shares for $21 each.
- On April 11, 2025, Christopher Anzalone, the company's CHIEF EXECUTIVE OFFICER sold 141.12K shares for $10.87 each.
Ownership Statistics for Arrowhead Pharmaceuticals Inc
Shares Outstanding
126.098M
Insider Shares Owned
8.420M
Insider Percentage Owned
6.13%
Institutional Shares Held
60.222M
Institutional Percentage Held
43.9%
| Apr 11, 2025 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | -141.12K | $10.87 | -$1.53M | SELL | -3.47% | 3.92M | Apr 09 - Apr 11 | View |
| Mar 17, 2025 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | 288.57K | $15.07 | -$774.97K | GRANT | 7.65% | 4.06M | Mar 13 | View |
| Mar 05, 2025 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | 0.00 | $12.67 | -$2.95M | SELL-OPTIONS | 0.00% | 3.77M | Mar 03 - Mar 04 | View |
| Jan 27, 2025 | Adeoye Olukotun | DIRECTOR | -959.00 | $21.00 | -$20.14K | SELL | -2.61% | 35.78K | Jan 23 | View |
| Jan 07, 2025 | James Hamilton | CHIEF DISCOVERY/TRANS MEDICINE | 67.27K | $19.82 | -$648.82K | GRANT | 32.84% | 272.12K | Jan 04 - Jan 06 | View |
| Jan 07, 2025 | Patrick O'Brien | COO AND GENERAL COUNSEL | 62.82K | $19.80 | -$736.06K | GRANT | 13.53% | 527.20K | Jan 04 - Jan 07 | View |
| Jan 07, 2025 | Kenneth Myszkowski | CHIEF FINANCIAL OFFICER | 54.83K | $19.77 | -$893.10K | GRANT | 13.69% | 455.43K | Jan 04 - Jan 07 | View |
| Jan 06, 2025 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | -11.52K | $19.05 | -$219.46K | SELL | -0.31% | 3.76M | Jan 02 | View |
| Dec 30, 2024 | Adeoye Olukotun | DIRECTOR | -2.85K | $20.00 | -$57.00K | SELL | -7.20% | 36.74K | Dec 27 | View |
| Dec 23, 2024 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | -12.56K | $19.59 | -$246.11K | SELL | -0.33% | 3.78M | Dec 23 | View |
| Dec 20, 2024 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | 73.29K | $21.24 | -$567.49K | GRANT | 1.97% | 3.79M | Dec 18 | View |
| Dec 18, 2024 | William Waddill | DIRECTOR | -7.50K | $21.97 | -$164.67K | SELL | -15.66% | 40.38K | Dec 16 - Dec 17 | View |
| Dec 18, 2024 | Douglass Given | DIRECTOR | -5.55K | $21.91 | -$121.56K | SELL | -4.28% | 124.17K | Dec 16 - Dec 17 | View |
| Dec 18, 2024 | Victoria Vakiener | DIRECTOR | -8.99K | $21.91 | -$197.06K | SELL | -29.78% | 21.21K | Dec 16 | View |
| Jul 03, 2024 | Tracie Oliver | CHIEF COMMERCIAL OFFICER | -9.39K | $25.28 | -$237.48K | SELL | -6.88% | 127.11K | Jul 02 | View |
| May 06, 2024 | Victoria Vakiener | DIRECTOR | -1.80K | $23.31 | -$41.93K | SELL | -5.62% | 30.20K | May 02 | View |
| Apr 03, 2024 | James Hamilton | CHIEF DISCOVERY/TRANS MEDICINE | -6.00K | $28.03 | -$168.18K | SELL | -2.85% | 204.85K | Apr 01 | View |
| Mar 20, 2024 | Hongbo Lu | DIRECTOR | 3.00K | $27.66 | $82.99K | BUY | 9.78% | 33.68K | Mar 18 - Mar 20 | View |
| Mar 08, 2024 | Kenneth Myszkowski | CHIEF FINANCIAL OFFICER | -40.00K | $35.19 | -$1.41M | SELL | -9.08% | 400.60K | Mar 06 | View |
| Feb 02, 2024 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | 0.00 | $23.44 | -$1.02M | SELL-OPTIONS | 0.00% | 3.72M | Jan 31 | View |
| Jan 17, 2024 | James Hamilton | CHIEF DISCOVERY/TRANS MEDICINE | -7.94K | $36.89 | -$292.90K | SELL | -3.63% | 210.85K | Jan 12 | View |
| Jan 16, 2024 | Douglass Given | DIRECTOR | -2.91K | $38.06 | -$110.79K | SELL | -2.19% | 129.71K | Jan 11 | View |
| Jan 16, 2024 | William Waddill | DIRECTOR | -3.93K | $38.07 | -$149.76K | SELL | -7.59% | 47.87K | Jan 11 | View |
| Jan 16, 2024 | Mauro Ferrari | DIRECTOR | -3.15K | $38.06 | -$119.79K | SELL | -4.92% | 60.78K | Jan 11 | View |
| Jan 16, 2024 | Victoria Vakiener | DIRECTOR | -4.72K | $38.10 | -$179.81K | SELL | -12.85% | 32.00K | Jan 11 | View |
| Jan 08, 2024 | Tracie Oliver | CHIEF COMMERCIAL OFFICER | 74.93K | $33.89 | -$2.51K | GRANT | 121.68% | 136.50K | Jan 04 - Jan 05 | View |
| Jan 08, 2024 | Kenneth Myszkowski | CHIEF FINANCIAL OFFICER | 58.90K | $35.27 | -$567.91K | GRANT | 15.43% | 440.60K | Jan 04 - Jan 05 | View |
| Jan 08, 2024 | Javier San Martin | CHIEF MEDICAL OFFICER | 66.70K | $35.26 | -$292.80K | GRANT | 50.60% | 198.50K | Jan 04 - Jan 05 | View |
| Jan 05, 2024 | James Hamilton | — | 36.56K | $34.69 | -$1.33M | GRANT | 20.06% | 218.79K | Jan 03 - Jan 05 | View |
| Jan 05, 2024 | Patrick O'Brien | COO AND GENERAL COUNSEL | 51.81K | $34.36 | -$1.14M | GRANT | 12.56% | 464.38K | Jan 03 - Jan 05 | View |
| Jan 04, 2024 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | -9.95K | $31.01 | -$308.64K | SELL | -0.27% | 3.72M | Jan 02 | View |
| Dec 22, 2023 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | -12.00K | $28.54 | -$342.48K | SELL | -0.32% | 3.73M | Dec 20 | View |
| Nov 22, 2023 | Javier San Martin | CHIEF MEDICAL OFFICER | -19.70K | $28.80 | -$567.32K | SELL | -13.00% | 131.80K | Nov 20 | View |
| Oct 27, 2023 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | -24.34K | $24.21 | -$589.22K | SELL | -0.65% | 3.74M | Oct 25 | View |
| Oct 02, 2023 | Victoria Vakiener | DIRECTOR | -1.55K | $26.33 | -$40.81K | SELL | -6.66% | 21.73K | Sep 28 | View |
| Sep 20, 2023 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | 0.00 | $16.44 | -$1.35M | SELL-OPTIONS | 0.00% | 3.76M | Sep 18 | View |
| Jul 06, 2023 | Tracie Oliver | CHIEF COMMERCIAL OFFICER | -8.93K | $35.31 | -$315.14K | SELL | -12.66% | 61.58K | Jul 03 | View |
| Jul 05, 2023 | James C Hamilton | — | -3.00K | $35.53 | -$106.59K | SELL | -1.57% | 188.48K | Jun 30 | View |
| Jun 29, 2023 | Kenneth Myszkowski | CHIEF FINANCIAL OFFICER | -15.00K | $36.20 | -$543.00K | SELL | -3.78% | 381.70K | Jun 27 | View |
| May 08, 2023 | Douglass Given | DIRECTOR | -6.50K | $40.90 | -$265.85K | SELL | -4.76% | 130.13K | May 05 | View |
| May 05, 2023 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | 0.00 | $20.66 | -$3.91M | SELL-OPTIONS | 0.00% | 3.76M | May 03 - May 04 | View |
| Mar 06, 2023 | Adeoye Olukotun | DIRECTOR | -11.35K | $32.65 | -$370.58K | SELL | -59.06% | 7.87K | Mar 03 | View |
| Mar 01, 2023 | Douglass Given | DIRECTOR | -875.00 | $32.62 | -$28.54K | SELL | -3.32% | 25.50K | Feb 27 | View |
| Jan 11, 2023 | William Waddill | DIRECTOR | 4.67K | $30.00 | -$96.00K | GRANT | 14.52% | 36.82K | Jan 09 - Jan 10 | View |
| Jan 06, 2023 | Patrick O'Brien | COO AND GENERAL COUNSEL | -15.00K | $37.39 | -$560.85K | SELL | -3.50% | 413.38K | Jan 05 | View |
| Jan 06, 2023 | James Hamilton | — | -13.80K | $37.40 | -$516.23K | SELL | -6.72% | 191.48K | Jan 05 | View |
| Jan 05, 2023 | Patrick O'Brien | COO AND GENERAL COUNSEL | 47.50K | $38.33 | -$670.80K | GRANT | 12.47% | 428.38K | Jan 03 - Jan 04 | View |
| Jan 05, 2023 | James Hamilton | — | 49.66K | $38.38 | -$396.74K | GRANT | 31.91% | 205.29K | Jan 03 - Jan 04 | View |
| Dec 30, 2022 | Kenneth Myszkowski | CHIEF FINANCIAL OFFICER | -30.63K | $40.00 | -$1.23M | SELL | -8.34% | 336.70K | Dec 29 | View |
| Nov 22, 2022 | Javier San Martin | CHIEF MEDICAL OFFICER | -19.50K | $29.99 | -$584.74K | SELL | -17.57% | 91.50K | Nov 21 | View |
| Feb 14, 2022 | Chris Anzalone | CHIEF EXECUTIVE OFFICER | 0.00 | $28.55 | -$6.84M | SELL-OPTIONS | 0.00% | 4.06M | Feb 11 | View |
| Jan 07, 2022 | Patrick O'Brien | GENERAL COUNSEL | -33.30K | $61.72 | -$2.01M | SELL | -8.73% | 348.07K | Dec 04 - Jan 05 | View |
| Jan 06, 2022 | Kenneth Myszkowski | CHIEF FINANCIAL OFFICER | -40.00K | $61.70 | -$2.47M | SELL | -7.94% | 464.00K | Jan 05 | View |
| Jan 06, 2022 | James Hamilton | — | -25.63K | $64.57 | -$1.65M | SELL | -14.14% | 155.63K | Jan 04 - Jan 05 | View |
| Jan 04, 2022 | William Waddill | DIRECTOR | -4.50K | $64.72 | -$291.24K | SELL | -14.88% | 25.75K | Jan 03 | View |
| Jan 04, 2022 | Adeoye Olukotun | DIRECTOR | -4.05K | $64.75 | -$262.23K | SELL | -45.00% | 4.95K | Jan 03 | View |
| Jan 04, 2022 | Marianne De Backer | DIRECTOR | -4.50K | $64.71 | -$291.18K | SELL | -20.93% | 17.00K | Jan 03 | View |
| Jan 04, 2022 | Michael Perry | DIRECTOR | -4.50K | $64.71 | -$291.19K | SELL | -5.00% | 85.50K | Jan 03 | View |
| Dec 29, 2021 | Douglass Given | DIRECTOR | 0.00 | $66.37 | $43.47K | GRANT | 0.00% | 122.37K | Dec 28 | View |
| Dec 29, 2021 | Mauro Ferrari | DIRECTOR | -3.40K | $66.82 | -$227.19K | SELL | -8.51% | 36.57K | Dec 28 | View |
| Dec 17, 2021 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | -60.00K | $67.56 | -$4.05M | SELL | -1.83% | 3.22M | Dec 15 | View |
| Nov 22, 2021 | Javier San Martin | CHIEF MEDICAL OFFICER | -19.50K | $69.31 | -$1.35M | SELL | -14.94% | 111.00K | Nov 19 | View |
| Oct 22, 2021 | Christopher Anzalone | CHIEF EXECUTIVE OFFICER | -65.00K | $65.77 | -$4.27M | SELL | -1.94% | 3.28M | Oct 20 - Oct 22 | View |
| Sep 14, 2021 | Adeoye Olukotun | DIRECTOR | -5.00K | $63.76 | -$318.80K | SELL | -35.71% | 9.00K | Sep 13 | View |
| Sep 10, 2021 | Douglass Given | DIRECTOR | -5.00K | $65.24 | -$326.20K | SELL | -3.93% | 122.37K | Sep 09 | View |
| Jun 25, 2021 | Marianne De Backer | DIRECTOR | -5.00K | $89.85 | -$449.25K | SELL | -18.87% | 21.50K | Jun 24 | View |
| Jun 24, 2021 | James Hassard | CHIEF COMMERCIAL OFFICER | -3.63K | $89.22 | -$323.42K | SELL | -3.31% | 105.75K | Jun 22 | View |
| Jun 24, 2021 | Douglass Given | DIRECTOR | -4.50K | $89.21 | -$401.44K | SELL | -3.41% | 127.37K | Jun 22 | View |
| Feb 24, 2021 | Douglass Given | DIRECTOR | -1.13K | $88.73 | -$99.82K | SELL | -4.09% | 26.38K | Feb 22 | View |
| Feb 10, 2021 | Patrick O'Brien | GENERAL COUNSEL | 0.00 | $46.84 | -$7.49M | SELL-OPTIONS | 0.00% | 293.38K | Feb 08 | View |
| Jan 19, 2021 | Douglass Given | DIRECTOR | -3.00K | $83.28 | -$249.84K | SELL | -9.84% | 27.50K | Jan 15 | View |
| Jan 15, 2021 | James C Hamilton | — | -10.00K | $81.29 | -$812.94K | SELL | -7.34% | 126.25K | Jan 14 | View |
| Jan 12, 2021 | Kenneth Myszkowski | CHIEF FINANCIAL OFFICER | -13.04K | $81.02 | -$1.06M | SELL | -2.85% | 444.00K | Jan 11 - Jan 12 | View |
| Jan 08, 2021 | James Hassard | CHIEF COMMERCIAL OFFICER | -15.63K | $75.00 | -$1.17M | SELL | -12.50% | 109.38K | Jan 07 | View |
| Jan 07, 2021 | Patrick O'Brien | GENERAL COUNSEL | -25.00K | $72.41 | -$1.81M | SELL | -7.85% | 293.38K | Jan 06 | View |
| Jan 07, 2021 | Kenneth Myszkowski | CHIEF FINANCIAL OFFICER | -30.63K | $72.44 | -$2.22M | SELL | -6.28% | 457.04K | Jan 06 | View |
| Jan 07, 2021 | James C Hamilton | — | -38.75K | $72.51 | -$2.81M | SELL | -22.14% | 136.25K | Jan 05 - Jan 06 | View |
| Jan 05, 2021 | Michael Perry | DIRECTOR | 5.00K | $76.09 | -$304.36K | GRANT | 5.88% | 90.00K | Jan 01 - Jan 04 | View |
| Jan 05, 2021 | Douglass Given | DIRECTOR | 5.50K | $76.08 | -$304.32K | GRANT | 4.83% | 119.37K | Jan 01 - Jan 04 | View |
| Jan 05, 2021 | William Waddill | DIRECTOR | 5.25K | $76.08 | -$285.30K | GRANT | 21.00% | 30.25K | Jan 01 - Jan 04 | View |
| Dec 18, 2020 | Douglass Given | — | -9.57K | $79.32 | -$759.44K | GIFT | -38.96% | 15.00K | Dec 07 - Dec 17 | View |
| Dec 11, 2020 | William Waddill | — | -3.00K | $71.26 | -$213.78K | SELL | -10.71% | 25.00K | Dec 10 | View |
| Dec 10, 2020 | Christopher Anzalone | — | 0.00 | $35.37 | -$3.67M | OPTION EXERCISE | 0.00% | 2.51M | Dec 08 - Dec 09 | View |
| Nov 23, 2020 | Curt Bradshaw | — | -31.25K | $69.06 | -$2.16M | SELL | -100.00% | 0.00 | Nov 19 - Nov 20 | View |
| Nov 20, 2020 | Javier San Martin | — | -19.50K | $69.39 | -$1.35M | SELL | -13.00% | 130.50K | Nov 19 | View |
| Nov 12, 2020 | Kenneth Myszkowski | — | 0.00 | $41.96 | -$2.39M | OPTION EXERCISE | 0.00% | 427.67K | Nov 09 | View |
| Oct 26, 2020 | Marianne De Backer | — | 1.00K | $50.47 | $50.47K | PURCHASE | 6.06% | 17.50K | Oct 08 | View |
| Oct 23, 2020 | Christopher Anzalone | — | -100.00K | $58.21 | -$5.82M | SELL | -3.84% | 2.51M | Oct 23 | View |
| Oct 22, 2020 | Kenneth Myszkowski | — | 0.00 | $30.09 | -$1.40M | OPTION EXERCISE | 0.00% | 427.67K | Oct 20 | View |
| Oct 13, 2020 | Mauro Ferrari | — | -10.00K | $48.00 | -$480.00K | SELL | -24.41% | 30.97K | Oct 09 | View |
| Aug 14, 2020 | Christopher Anzalone | — | 0.00 | $25.63 | -$1.57M | OPTION EXERCISE | 0.00% | 2.61M | Aug 13 | View |
| Jun 26, 2020 | Christopher Anzalone | — | -100.00K | $38.81 | -$3.88M | SELL | -3.70% | 2.61M | Jun 25 | View |
| Jun 24, 2020 | Marianne De Backer | — | 4.00K | $33.56 | $134.24K | PURCHASE | 32.00% | 16.50K | Jan 13 - Jun 15 | View |
| May 13, 2020 | Michael Perry | — | -36.00K | $35.83 | -$1.29M | SELL | -81.82% | 8.00K | May 12 | View |
| May 13, 2020 | William Waddill | — | -26.00K | $36.54 | -$950.04K | SELL | -48.15% | 28.00K | May 11 | View |
| Apr 29, 2020 | /S/ Bruce Given | — | -1.00K | $24.23 | -$178.87K | OPTION EXERCISE | -0.12% | 850.73K | Apr 27 - Apr 28 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.
